Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296696131> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4296696131 abstract "ABSTRACT Although over 12 billion COVID-19 vaccine doses have been administered globally, the important issue of whether the optimal doses are being used has been relatively neglected. To address this question, we reviewed the reports of early-phase dose-finding trials of the nine COVID-19 vaccines approved by World Health Organization (and one additional vaccine which showed partial clinical efficacy), extracting information on study design and findings on reactogenicity and early humoral immune response. The number of different doses evaluated per vaccine varied widely (range 1-7), as did the number of subjects studied per dose (range 15-190). As expected, the frequency and severity of adverse reactions generally increased at higher doses, although most were clinically tolerable. Higher doses also tended to elicit better immune responses, but differences between the maximum dose and the second-highest dose evaluated were small, typically less than 1.6-fold for both binding antibody concentration and neutralising antibody titre. All of the trials had at least one important design limitation: few doses evaluated, large gaps between adjacent doses, or an inadequate sample size. In general, it is therefore uncertain whether the single dose taken into clinical efficacy trials, and subsequently authorised by regulatory agencies, was optimal. In particular, the recommended doses for some vaccines appear to be unnecessarily high. Although reduced dosing for booster injections is an active area of research, the priming dose is equally deserving of study. We conclude by suggesting some ways in which the design of future trials of candidate COVID-19 vaccines could be improved." @default.
- W4296696131 created "2022-09-23" @default.
- W4296696131 creator A5024782736 @default.
- W4296696131 creator A5040052939 @default.
- W4296696131 creator A5053823377 @default.
- W4296696131 creator A5085619123 @default.
- W4296696131 date "2022-09-22" @default.
- W4296696131 modified "2023-10-16" @default.
- W4296696131 title "Dose of approved COVID-19 vaccines is based on weak evidence: a review of early-phase, dose-finding trials" @default.
- W4296696131 cites W1996099497 @default.
- W4296696131 cites W2099447036 @default.
- W4296696131 cites W2153448193 @default.
- W4296696131 cites W2164151960 @default.
- W4296696131 cites W3011078950 @default.
- W4296696131 cites W3042383115 @default.
- W4296696131 cites W3042833857 @default.
- W4296696131 cites W3043722389 @default.
- W4296696131 cites W3081892744 @default.
- W4296696131 cites W3092766467 @default.
- W4296696131 cites W3093367571 @default.
- W4296696131 cites W3096510866 @default.
- W4296696131 cites W3102328262 @default.
- W4296696131 cites W3111590711 @default.
- W4296696131 cites W3119345685 @default.
- W4296696131 cites W3128853581 @default.
- W4296696131 cites W3135734644 @default.
- W4296696131 cites W3175475609 @default.
- W4296696131 cites W3181348778 @default.
- W4296696131 cites W3197521081 @default.
- W4296696131 cites W3214570601 @default.
- W4296696131 cites W3215521526 @default.
- W4296696131 cites W3217661335 @default.
- W4296696131 cites W4206097200 @default.
- W4296696131 cites W4226343533 @default.
- W4296696131 doi "https://doi.org/10.1101/2022.09.20.22276701" @default.
- W4296696131 hasPublicationYear "2022" @default.
- W4296696131 type Work @default.
- W4296696131 citedByCount "0" @default.
- W4296696131 crossrefType "posted-content" @default.
- W4296696131 hasAuthorship W4296696131A5024782736 @default.
- W4296696131 hasAuthorship W4296696131A5040052939 @default.
- W4296696131 hasAuthorship W4296696131A5053823377 @default.
- W4296696131 hasAuthorship W4296696131A5085619123 @default.
- W4296696131 hasBestOaLocation W42966961311 @default.
- W4296696131 hasConcept C126322002 @default.
- W4296696131 hasConcept C197934379 @default.
- W4296696131 hasConcept C203014093 @default.
- W4296696131 hasConcept C2777288759 @default.
- W4296696131 hasConcept C2777704310 @default.
- W4296696131 hasConcept C2779134260 @default.
- W4296696131 hasConcept C2780868878 @default.
- W4296696131 hasConcept C3008058167 @default.
- W4296696131 hasConcept C524204448 @default.
- W4296696131 hasConcept C535046627 @default.
- W4296696131 hasConcept C71924100 @default.
- W4296696131 hasConcept C8891405 @default.
- W4296696131 hasConcept C98274493 @default.
- W4296696131 hasConceptScore W4296696131C126322002 @default.
- W4296696131 hasConceptScore W4296696131C197934379 @default.
- W4296696131 hasConceptScore W4296696131C203014093 @default.
- W4296696131 hasConceptScore W4296696131C2777288759 @default.
- W4296696131 hasConceptScore W4296696131C2777704310 @default.
- W4296696131 hasConceptScore W4296696131C2779134260 @default.
- W4296696131 hasConceptScore W4296696131C2780868878 @default.
- W4296696131 hasConceptScore W4296696131C3008058167 @default.
- W4296696131 hasConceptScore W4296696131C524204448 @default.
- W4296696131 hasConceptScore W4296696131C535046627 @default.
- W4296696131 hasConceptScore W4296696131C71924100 @default.
- W4296696131 hasConceptScore W4296696131C8891405 @default.
- W4296696131 hasConceptScore W4296696131C98274493 @default.
- W4296696131 hasLocation W42966961311 @default.
- W4296696131 hasOpenAccess W4296696131 @default.
- W4296696131 hasPrimaryLocation W42966961311 @default.
- W4296696131 hasRelatedWork W1993922806 @default.
- W4296696131 hasRelatedWork W206168401 @default.
- W4296696131 hasRelatedWork W2947337648 @default.
- W4296696131 hasRelatedWork W3026647284 @default.
- W4296696131 hasRelatedWork W3115932594 @default.
- W4296696131 hasRelatedWork W3122374068 @default.
- W4296696131 hasRelatedWork W4211020048 @default.
- W4296696131 hasRelatedWork W4220952552 @default.
- W4296696131 hasRelatedWork W4282941962 @default.
- W4296696131 hasRelatedWork W4296696131 @default.
- W4296696131 isParatext "false" @default.
- W4296696131 isRetracted "false" @default.
- W4296696131 workType "article" @default.